Press Releases & News

Brings 30-years of Experience to Company’s Technology Development and Manufacturing Operations

AUSTIN, Texas–(BUSINESS WIRE)–Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointment of Donna Rill as Chief Technology Officer. As CTO, Rill will use her extensive technology development and manufacturing experience to help drive Triumvira’s clinical development programs.

Ms. Rill is an accomplished expert in cellular therapy manufacturing and has held responsibility for the design and qualification of cell and gene therapy laboratories using novel technologies, as well as production, service and research type laboratories. In addition to her construction, project management and regulatory/quality assurance and control knowledge, she brings extensive operational and strategic experience in cell and gene therapy, and antibody and protein production.

Read Complete Article »